Centarix Biotech

Company Overview

Snapshot

Founded in May 2017 by Shimon Meshi, Itzhak Dershowitz, and Noam Maoz, Centarix Biotech operates with 11–50 employees. The company has raised $30 million across one funding round, reaching a Series A stage. Centarix Biotech is actively advancing gene therapy to slow and reverse the aging process.

Business overview

Centarix Biotech is a cutting-edge biotech company focused on enhancing health and performance by addressing the fundamental mechanisms of aging. The company develops gene therapies designed to slow and reverse the aging process at a molecular level. Complementing its therapeutic efforts, Centarix Biotech also creates precise and comprehensive aging diagnostics to evaluate the effectiveness of various interventions. These advanced diagnostics and data analysis form the foundation for its longevity clinics, which aim to provide proven and effective longevity treatments to clients globally. Centarix Biotech operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving B2C, B2B2C, and B2B markets across North America, Europe, Asia, and South America.

Company Intelligence Q&A

When was Centarix Biotech founded?

Centarix Biotech was founded in May 2017.

Who are the founders of Centarix Biotech?

The founders of Centarix Biotech are Shimon Meshi, Itzhak Dershowitz, and Noam Maoz.

What is Centarix Biotech's primary focus?

Centarix Biotech focuses on increasing health and performance by slowing down and reversing the aging process through gene therapy and advanced diagnostics.

What is the total capital raised by Centarix Biotech?

Centarix Biotech has raised a total of $30 million across one funding round.

What markets does Centarix Biotech serve?

Centarix Biotech serves geomarkets in North America, Europe, Asia, and South America.